Summary
Angel Biotechnology Holdings, the Aim-listed biopharmaceutical contract manufacturer, released interim results for the half year to June 30. Revenues increased 263% to pounds 755,000 compared with the same time last year and after a pounds 5,000 research and development tax credit the company made a loss of pounds 821,000.
Chairman Dr Paul Harper said revenue was below expectations because of a potential client delaying signing a contract and the handover of a new factory at Cramlington being delayed three months. As a result of the delay in getting the plant from the builders, the company incurred unplanned spending in gaining a licence from the Medicines and Healthcare products Regulatory Agency (MHRA).See the full content of this document
Extract
Angel Downcast by Plant Delay
A direct consequence of this delay has been the lost opportun...
See the full content of this document
Sponsored links
